Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Razvan Cristescu

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Vaccine|October 16, 2012
Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza VaccineEugene Maraskovsky, Steve Rockman, Allison Dyson, et al.
Nature Medicine|June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trialThomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Virology|May 22, 2012
Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesisAngela L Rasmussen, I-Ming Wang, Margaret C Shuhart, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
NPJ Breast Cancer|October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapyJavier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
Molecular Cancer Therapeutics|June 4, 2016
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to VintafolideAmy D Guertin, Jennifer O'Neil, Alexander Stoeck, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Vaccine|October 16, 2012
Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza VaccineEugene Maraskovsky, Steve Rockman, Allison Dyson, et al.
Nature Medicine|June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trialThomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Virology|May 22, 2012
Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesisAngela L Rasmussen, I-Ming Wang, Margaret C Shuhart, et al.
Breast Cancer Research : BCR|March 12, 2025
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 studyRebecca Dent, Javier Cortés, Yeon Hee Park, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
NPJ Breast Cancer|October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapyJavier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
Molecular Cancer Therapeutics|June 4, 2016
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to VintafolideAmy D Guertin, Jennifer O'Neil, Alexander Stoeck, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Pageof 6